Biotech stocks are companies that use living organisms to make drugs and vaccines. Often, they merge cutting-edge technology with new findings in molecular science and virology to treat life ...
UPPAL K V RANGAREDDY Pin Code is 500039. UPPAL K V RANGAREDDY is located in NA K V RANGAREDDY, TELANGANA, India. What is the contact address for UPPAL K V RANGAREDDY Post Office, TELANGANA? UPPAL K V ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...
Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...
The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers.
Evneet Uppal has joined Aarna Law as a Partner in Disputes practice at the firm's Delhi office. She will be heading the firm's disputes practice in Delhi. Loading content, please wait ...
Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...
Prolium was set up by RTW in 2024. Last year also saw the New York-based investment fund involved in the launch of obesity biotech Kailera Therapeutics, which RTW said at the time was the fourth ...
But local biotech leaders see signs of change in 2025. Amid tough biotech industry market conditions last year, investors and Big Pharma companies were more likely to make deals with later-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback